5'-FluoroindirubinoximeFLT3 inhibitor; displays antiproliferative activity CAS# 861214-33-7 |
- Verteporfin
Catalog No.:BCC3690
CAS No.:129497-78-5
- Miglustat hydrochloride
Catalog No.:BCC5186
CAS No.:210110-90-0
- Hydrochlorothiazide
Catalog No.:BCC4786
CAS No.:58-93-5
- Miglustat
Catalog No.:BCC5187
CAS No.:72599-27-0
- TPT-260
Catalog No.:BCC5171
CAS No.:769856-81-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 861214-33-7 | SDF | Download SDF |
PubChem ID | 11580208 | Appearance | Powder |
Formula | C16H10FN3O2 | M.Wt | 295.27 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 83.33 mg/mL (282.22 mM; Need ultrasonic) | ||
Chemical Name | 5-fluoro-3-[3-(hydroxyamino)-1H-indol-2-yl]indol-2-one | ||
SMILES | C1=CC=C2C(=C1)C(=C(N2)C3=C4C=C(C=CC4=NC3=O)F)NO | ||
Standard InChIKey | LBUXOYSDWHGJNP-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H10FN3O2/c17-8-5-6-12-10(7-8)13(16(21)19-12)15-14(20-22)9-3-1-2-4-11(9)18-15/h1-7,18,20,22H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Inhibitor of FMS-like receptor tyrosine kinase-3 (FLT3) (IC50 = 15 nM). Displays selectivity for FLT3 against 6 other kinases including EGFR. Displays antiproliferative activity against the MV4;11 cell line (expressing constitutively active FLT3) and a number of cancer cell lines, including SNU-638 (stomach carcinoma) and HT-1080 (fibrosarcoma). |
5'-Fluoroindirubinoxime Dilution Calculator
5'-Fluoroindirubinoxime Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.3867 mL | 16.9337 mL | 33.8673 mL | 67.7346 mL | 84.6683 mL |
5 mM | 0.6773 mL | 3.3867 mL | 6.7735 mL | 13.5469 mL | 16.9337 mL |
10 mM | 0.3387 mL | 1.6934 mL | 3.3867 mL | 6.7735 mL | 8.4668 mL |
50 mM | 0.0677 mL | 0.3387 mL | 0.6773 mL | 1.3547 mL | 1.6934 mL |
100 mM | 0.0339 mL | 0.1693 mL | 0.3387 mL | 0.6773 mL | 0.8467 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- A 844606
Catalog No.:BCC6200
CAS No.:861119-08-6
- M617
Catalog No.:BCC5929
CAS No.:860790-38-1
- Fmoc-Trp-OPfp
Catalog No.:BCC3557
CAS No.:86069-87-6
- Fmoc-β-Homo-Pro-OH
Catalog No.:BCC2627
CAS No.:86069-86-5
- Fmoc-Glu(OtBu)-OPfp
Catalog No.:BCC3495
CAS No.:86061-04-3
- Fmoc-Asp(OtBu)-OPfp
Catalog No.:BCC3091
CAS No.:86061-01-0
- Fmoc-Gln-OPfp
Catalog No.:BCC3484
CAS No.:86061-00-9
- Fmoc-Asn-OPfp
Catalog No.:BCC3080
CAS No.:86060-99-3
- Fmoc-Lys(Boc)-OPfp
Catalog No.:BCC3517
CAS No.:86060-98-2
- Fmoc-Cys(Acm)-OPfp
Catalog No.:BCC3474
CAS No.:86060-96-0
- Fmoc-Met-OPfp
Catalog No.:BCC3529
CAS No.:86060-94-8
- Fmoc-Tyr(tBu)-OPfp
Catalog No.:BCC3568
CAS No.:86060-93-7
- Fmoc-D-Phe-OH
Catalog No.:BCC3537
CAS No.:86123-10-6
- Fmoc-D-Trp-OH
Catalog No.:BCC3559
CAS No.:86123-11-7
- SKF 86466 hydrochloride
Catalog No.:BCC7795
CAS No.:86129-54-6
- A-740003
Catalog No.:BCC1322
CAS No.:861393-28-4
- 2''-O-Beta-L-Galorientin
Catalog No.:BCN3804
CAS No.:861691-37-4
- 7-Methoxy-3,4-dihydro-1-naphthalenylacetonitrile
Catalog No.:BCC8781
CAS No.:861960-34-1
- Anamorelin hydrochloride
Catalog No.:BCC1364
CAS No.:861998-00-7
- Nandrolone undecylate
Catalog No.:BCC9090
CAS No.:862-89-5
- Mirodenafil
Catalog No.:BCC5254
CAS No.:862189-95-5
- Valeriotriate B
Catalog No.:BCN6751
CAS No.:862255-64-9
- RA VII
Catalog No.:BCN3512
CAS No.:86229-97-2
- Imatinib hydrochloride
Catalog No.:BCC1644
CAS No.:862366-25-4
Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.[Pubmed:20153646]
Bioorg Med Chem Lett. 2010 Mar 15;20(6):2033-7.
Indirubin derivatives were identified as potent FLT3 tyrosine kinase inhibitors with anti-proliferative activity at acute myeloid leukemic cell lines, RS4;11 and MV4;11 which express FLT3-WT and FLT3-ITD mutation, respectively. Among several 5 and 5'-substituted indirubin derivatives, 5-fluoro analog, 13 exhibited potent inhibitory activity at FLT3 (IC(50)=15 nM) with more than 100-fold selectivity versus 6 other kinases and potent anti-proliferative effect for MV4;11 cells (IC(50)=72 nM) with 30-fold selectivity versus RS4;11 cells. Cell cycle analysis indicated that compound 13 induced cell cycle arrest at G(0)/G(1) phase in MV4;11 cells.
Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs.[Pubmed:18824607]
Antimicrob Agents Chemother. 2008 Dec;52(12):4466-9.
New drugs are needed for treatment of Toxoplasma gondii infections. We tested derivatives of principles found in Isatis indigotica for in vitro efficacy against T. gondii infection. Indirubin-3'-oxime analogs showed modest micromolar activity, while tryptanthrin derivatives displayed 50% inhibitory doses in the low nanomolar range. Tryptanthrins have potential as anti-Toxoplasma infection therapeutics.
Antitumor activity of novel indirubin derivatives in rat tumor model.[Pubmed:17200363]
Clin Cancer Res. 2007 Jan 1;13(1):253-9.
PURPOSE: The novel indirubin derivatives 5'-nitro-indirubinoxime, 5'-fluoro-indirubinoxime, and 5'-trimethylacetamino-indirubinoxime were designed and tested for antitumor activity both in vitro and in vivo using rat tumor model. EXPERIMENTAL DESIGN: Three-week-old male Sprague-Dawley rats were inoculated s.c. on the left flank with 10(7) RK3E-ras rat kidney epithelial cells harboring k-ras gene. Alternatively, 5 x 10(6) RK3E-ras cells were injected into the oral mucosa. Indirubin derivative treatment began on the 3rd or 6th day after oral or s.c. cell injection, respectively. Indirubin derivatives were directly injected into the tumor every other day for a total of five times. Animals were monitored daily and tumor volume was measured by caliper. RESULTS: Indirubin derivatives showed potent antiproliferative activity on various human cancer cells and oncogenic RK3E-ras rat kidney cells, with IC(50) ranging from 1 to 12 mumol/L. Treatment with indirubin derivatives induced the activation of caspase-7 followed by apoptosis in RK3E-ras cells. Indirubin derivatives showed strong antitumor activity in rat solid and oral tumor models. Direct injection of indirubin derivatives every other day for 10 days induced significant inhibition of tumor growth in Sprague-Dawley rats bearing RK3E-ras-induced tumors. Histologically, treatment with indirubin derivatives caused significant inhibition of tumor formation with increased apoptosis and decreased tumor cell proliferation. CONCLUSIONS: Our data showed that novel indirubin derivatives 5'-nitro-indirubinoxime, 5'-fluoro-indirubinoxime, and 5'-trimethylacetamino-indirubinoxime effectively arrested the tumor growth by inhibiting cell proliferation and inducing apoptosis. These findings provide the potential value of indirubin derivatives as novel candidates for antitumor agents.